OssDsign appoints Tom Buckland as Chief Technical Officer

February 29, 2024 – OssDsign AB (publ.) today announces that the company’s current VP of Strategy, Business Development and Regulatory Affairs, Tom Buckland, has been appointed Chief Technical Officer (CTO). The promotion is a key part of the company’s change of direction into a pure-play orthobiologics company focusing exclusively on the U.S. Market.

Tom Buckland, currently VP of Strategy, Business Development and Regulatory Affairs, will in his new role be responsible for Operations & Manufacturing, Research & Development as well as Quality Assurance and Regulatory Affairs.

“Since the Acquisition of Sirakoss in 2020, Tom Buckland has been an instrumental member of the team. Appointing him as our new CTO is an important step in OssDsign’s transformation into a pureplay orthobiologics company. His scientific background combined with his vast operational experience from leading positions in spine and orthobiologics companies will be pivotal for the company’s journey forward”, said Morten Henneveld, CEO of OssDsign.

Tom Buckland joined OssDsign through the acquisition of Sirakoss, where he was the CEO. His previous experiences include leading positions at Nuvasive, Apatech and Baxter as well as working as a reputable advisor to start- and scale-up companies. Tom Buckland holds a Masters’ degree in Mechanical Engineering and a Ph.D. in Biomaterials from the University of London.

For further information, please contact:

Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email:

Certified Adviser

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)

About OssDsign

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button